Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Summa Akron City Hospital/Cooper Cancer Center
mi
from
Akron, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Women and Infants Hospital
mi
from
Providence, RI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated:  3/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Status: Enrolling
Updated: 3/20/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated:  3/21/2018
Swedish Medical Center Cancer Institute
mi
from
Seattle, WA
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated: 3/21/2018
Swedish Medical Center Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated:  3/21/2018
Swedish Cancer Institute Edmonds Campus
mi
from
Edmonds, WA
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated: 3/21/2018
Swedish Cancer Institute Edmonds Campus
mi
from
Edmonds, WA
Click here to add this to my saved trials
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated:  3/21/2018
Swedish Cancer Institute Issaquah Campus
mi
from
Issaquah, WA
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated: 3/21/2018
Swedish Cancer Institute Issaquah Campus
mi
from
Issaquah, WA
Click here to add this to my saved trials
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated:  3/21/2018
Pacific Gynecology Specialists
mi
from
Seattle, WA
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated: 3/21/2018
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated:  3/21/2018
Swedish Cancer Institute Ballard Campus
mi
from
Seattle, WA
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients
Status: Enrolling
Updated: 3/21/2018
Swedish Cancer Institute Ballard Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated:  3/22/2018
Tom Baker Cancer Centre
mi
from
Calgary,
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
Status: Enrolling
Updated: 3/22/2018
Tom Baker Cancer Centre
mi
from
Calgary,
Click here to add this to my saved trials
Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer
Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer
Status: Enrolling
Updated:  3/26/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer
Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer
Status: Enrolling
Updated: 3/26/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
The Hartford Hospital
mi
from
Hartford, CT
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Jupiter Medical Center
mi
from
Jupiter, FL
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Jupiter Medical Center
mi
from
Jupiter, FL
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Florida Hospital
mi
from
Orlando, FL
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Memorial Health University Medical Center
mi
from
Savannah, GA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Northwestern University
mi
from
Chicago, IL
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Univ of Illinois
mi
from
Chicago, IL
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
University of Chicago
mi
from
Chicago, IL
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Saint Vincent Hospital and Health Services
mi
from
Indianapolis, IN
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Saint Vincent Hospital and Health Services
mi
from
Indianapolis, IN
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Providence Medical Center
mi
from
Kansas City, KA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Providence Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Lawrence Memorial Hospital
mi
from
Lawrence, KA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Radiation Oncology Center of Olathe
mi
from
Olathe, KA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Radiation Oncology Center of Olathe
mi
from
Olathe, KA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Menorah Medical Center
mi
from
Overland Park, KA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Menorah Medical Center
mi
from
Overland Park, KA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Radiation Oncology Practice Corporation Southwest
mi
from
Overland Park, KA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Radiation Oncology Practice Corporation Southwest
mi
from
Overland Park, KA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Franklin Square Hospital Center
mi
from
Baltimore, MD
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Franklin Square Hospital Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Green Bay Oncology - Escanaba
mi
from
Escanaba, MI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Green Bay Oncology - Escanaba
mi
from
Escanaba, MI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Green Bay Oncology - Iron Mountain
mi
from
Iron Mountain, MI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Green Bay Oncology - Iron Mountain
mi
from
Iron Mountain, MI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Centerpoint Medical Center LLC
mi
from
Independence, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Centerpoint Medical Center LLC
mi
from
Independence, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Truman Medical Center
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Truman Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Saint Luke's Cancer Institute
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Saint Luke's Cancer Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Radiation Oncology Practice Corporation South
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Radiation Oncology Practice Corporation South
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Saint Joseph Health Center
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Saint Joseph Health Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
North Kansas City Hospital
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
North Kansas City Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Research Medical Center
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Radiation Oncology Practice Corporation - North
mi
from
Kansas City, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Radiation Oncology Practice Corporation - North
mi
from
Kansas City, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Liberty Hospital
mi
from
Liberty, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Liberty Hospital
mi
from
Liberty, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Heartland Regional Medical Center
mi
from
Saint Joseph, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Heartland Regional Medical Center
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Southwest Gynecologic Oncology Associates
mi
from
Albuquerque, NM
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Southwest Gynecologic Oncology Associates
mi
from
Albuquerque, NM
Click here to add this to my saved trials